GlassScriptPhysician profile
Moshe Frances
NPI 1417626870
$7,352.17
in general payments reported to CMS, 2019-2025
21 companies · $1,425 in 2025
The $1,425 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,874 · 2023: $2,503 · 2024: $1,551 · 2025: $1,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,391 · Education: $87.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,391.09 |
| Education | $87.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,635.11 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,130.91 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,020.18 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $728.95 | 2022-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $644.98 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $564.86 | 2022-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $432.50 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $301.09 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $233.29 | 2022-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $208.63 | 2023-2024 | Qelbree, Qelbree |
| Indivior INC. | $110.67 | 2022-2025 | Sublocade, Perseris |
| Boston Scientific Corporation | $87.42 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Braeburn INC. | $85.64 | 2023-2025 | Brixadi |
| Corium, LLC | $38.25 | 2022-2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $31.46 | 2024 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $28.36 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.18 | 2022 | |
| Lundbeck LLC | $14.93 | 2025 | Rexulti |
| Almatica Pharma LLC | $14.40 | 2025 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $13.16 | 2022 | |
| Noven Therapeutics, LLC | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshe Frances listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.